News and Announcements
OpenDNA & Epoch Times MoU Set to Offer Its 20 Million Readers with Better Tailored Reader Content Using Artificial Intelligence Technologies
- Published October 03, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
KEY TAKEAWAYS:
- A Memorandum of Understanding (MOU) was signed between OpenDNA and The Epoch Times.
- The MOU, which will last for three months, will allow OpenDNA to use its artificial intelligence technology to gain insight into the subscribers and online readers of The Epoch Times, to help the latter provide more personalised news content for its readers.
- The trial period could turn into a long-term agreement if both parties find it viable.
- Once a long-term agreement is signed, OpenDNA will be entitled to a percentage of The Epoch Times revenues.
The signing of a Memorandum of Understanding (MOU) between OpenDNA and The Epoch Times is expected to provide a more personalised service to the newspaper company’s readers.
OpenDNA is an artificial intelligence company based in Australia while The Epoch Times is a multi-language newspaper based in New York City that is published in 21 languages all over 35 countries.
Under the MOU, OpenDNA will use its artificial intelligence services to gather the insights of millions of subscribers and online readers of The Epoch Times to help the newspaper deliver a more personalised news content for its readers.
“We are extremely proud and excited to work with a publisher of the calibre of Epoch Times, whose purpose and values are very much aligned to our own, specifically putting the individual reader first,” OpenDNA Managing Director and CEO Jay Shah said.
Shah said this is a massive opportunity for OpenDNA considering the 20 million readers of The Epoch Times. He said the company’s technology will help facilitate the continued growth of the newspaper’s readership as it gets a better insight of its readers. Providing personalised content based on the readers’ likes and dislikes is expected to result in higher reader retention and in the process more revenue for the newspaper.
With the MOU, OpenDNA will be able to integrate its technology into the digital platform of The Epoch Times for a 90-day period. This will allow the newspaper to deliver personalised and tailor-made news and advertising to individual readers during the said period.
Both parties have agreed to enter into a customer agreement once the trial period is deemed successful. The signing of an ongoing agreement will entitle OpenDNA to a percentage of the revenues derived by the newspaper not only from First Party Data Insights but also from advertising and the user-based licensing fees.
“Our mission is to be an independent voice in print and on the web. We report news responsibly, truthfully and we are a business that puts our readers’ interests first. Through the implementation of OpenDNA’s leading-edge technology, we will gain further insights into the interests, likes and dislikes of each of our readers, down to an individual level, which will ultimately enable us as a publisher to deliver to each of our readers the most relevant and engaging content,” The Epoch Times Director of Digital Marketing Lukas Chudy said.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
